Martin Nutraceuticals Announces Clinical Trail Results for Weight Loss and Obesity Control With New Product


RENO, Nev., May 17, 2005 (PRIMEZONE) -- Martin Nutraceuticals Inc. (Pink Sheets:MTNU) is pleased to announce the initial results of a clinical trial for weight loss using a proprietary formula, Maximum Slim(tm), developed by Dr. A. W. Martin for Martin Nutraceuticals Inc.

In this 4-week clinical trial, half the patients were given 6 Maximum Slim(tm) capsules -- two with every meal, and the other half were given a placebo. The group using Maximum Slim(tm) lost an average of 3% body fat, while the placebo group averaged less than 0.5% body fat.

Maximum Slim(tm) is an all natural dietary supplement consisting of proprietary herbs and nutraceuticals that stimulate fat loss by binding fat, suppressing hunger and boosting metabolism, all with no stimulants and no known side effects.

"We are very excited about the possibilities that lie in the weight loss industry," states Dr. A.W. Martin, "The weight loss industry itself is a market that is approximately $100 billion in size, effectively stating that people are conscious about the way they look and want to maintain a healthy lifestyle; Maximum Slim helps achieve this."

Dr. Martin is a Canadian nutritional researcher and author of several books, including "The New Thin You, Naturally."

Martin Nutraceuticals Inc.'s Maximum Slim(tm) will be available in retail outlets in the third quarter of this year.

Forward Looking Statements

The management of the company, who take full responsibility for its content, prepared this press release. Statements in this news release concerning the company's business outlook or future economic performance, anticipated profitability, revenues, expenses, or other financial items; and statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements" as that term is defined under the Federal Securities Laws. Forward-looking statements are subject to risks, uncertainties and other factors which could cause actual results to differ materially from those contained in such statements. Such risks, uncertainties and factors include, but are not limited to, future capital needs, changes and delays in product development plans and schedules, customer acceptance of new products, changes in pricing or other actions by competitors, and general economic conditions.


            

Contact Data